title: Erythrocyte membrane phosphatidylserine exposure in obesity.
abstract: It has been suggested that increased erythrocyte membrane phosphatidylserine (PS) exposure could contribute to hypercoagulability and hemorheological disturbances in obesity. The aim of our study was to evaluate PS exposure in obese patients and in a control group and to correlate this with hemorheological properties, i.e., erythrocyte aggregability (EA) and deformability, and to evaluate the effect of weight loss on these parameters. An anthropometric and analytical evaluation was performed at baseline and after 3 months on a diet (very low-calorie diet for 4 weeks and low-calorie diet for 2 months) on 49 severe or morbid obese patients (37 women, 12 men) and 55 healthy volunteers (39 women, 16 men). PS exposure on erythrocyte membrane was performed by flow cytometry. Erythrocyte aggregation was measured using the Myrenne MA(1) and the Sefam aggregometer. Erythrocyte deformability was determined in a stress diffractometer. Prothrombin fragment F1+2 (F1+2) was determined as a marker of the hypercoagulable state, and plasma malondialdehyde (MDA) as an indicator of oxidative stress. Obese patients had a higher EA index, higher PS exposure on erythrocyte membranes and higher levels of MDA and F1+2. The differences in erythrocyte aggregation and F1+2 between obese patients and the control group were maintained after adjusting for PS exposure. After 3 months of diet, a significant reduction in PS exposure on erythrocyte membrane was observed. Obese patients show increased PS exposure on erythrocyte membrane, with no effect on rheological properties. Increased PS exposure could contribute to hypercoagulability in these patients. Weight loss obtained with diet treatment reduces PS exposure on erythrocyte membrane.
authors.affiliation: Endocrinology Service, Doctor Peset University Hospital, Valencia, Spain. solaeva@gva.es
authors.forename: Eva
authors.initials: E
authors.lastname: Solá
authors.forename: Amparo
authors.initials: A
authors.lastname: Vayá
authors.forename: Marcial
authors.initials: M
authors.lastname: Martínez
authors.forename: Antonio
authors.initials: A
authors.lastname: Moscardó
authors.forename: Dolores
authors.initials: D
authors.lastname: Corella
authors.forename: Maria-Luisa
authors.initials: ML
authors.lastname: Santaolaria
authors.forename: Francisco
authors.initials: F
authors.lastname: España
authors.forename: Antonio
authors.initials: A
authors.lastname: Hernández-Mijares
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D004903:Erythrocyte Aggregation / Q000502:physiology*; D004907:Erythrocyte Deformability / Q000502:physiology*; D004910:Erythrocyte Membrane / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D018384:Oxidative Stress / Q000502:physiology; D010446:Peptide Fragments / Q000378:metabolism; D010718:Phosphatidylserines / Q000378:metabolism*; D011498:Protein Precursors / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D015431:Weight Loss / Q000502:physiology; D055815:Young Adult
chemical_list: D010446:Peptide Fragments; D010718:Phosphatidylserines; D011498:Protein Precursors; D008315:Malondialdehyde; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D011516:Prothrombin